NQO1 and COVID-19: There is emerging evidence, however, that NQO1 expression may be altered post–COVID-19 in the context of neuroinflammatory processes, but this relates to post-infection neurological effects rather than serving as a prognostic blood biomarker during acute COVID-19 (Yang et al., 2021; Hamdy et al., 2022).